NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
NEXGEL reported record Q3 2024 revenue of $2.94 million, marking a 141% year-over-year and 104% sequential increase. The growth was driven by approximately 100% sequential increases in both branded consumer products and contract manufacturing. Gross profit margin improved to 43.6% from 28.2% in Q3 2023. The company reported a net loss of $754,000 and an Adjusted EBITDA loss of $347,000. Cash balance stood at $1.10 million, with an additional $2 million raised through a registered direct offering post-quarter.
NEXGEL ha riportato un fatturato record per il Q3 2024 di 2,94 milioni di dollari, con un aumento del 141% rispetto all'anno precedente e del 104% rispetto al trimestre precedente. La crescita è stata sostenuta da un aumento sequenziale di circa il 100% sia nei prodotti di consumo a marchio che nella produzione su contratto. Il margine di profitto lordo è migliorato al 43,6% rispetto al 28,2% del Q3 2023. L'azienda ha registrato una perdita netta di 754.000 dollari e una perdita di EBITDA rettificato di 347.000 dollari. Il saldo di cassa si attestava a 1,10 milioni di dollari, con ulteriori 2 milioni di dollari raccolti tramite un'offerta diretta registrata dopo il trimestre.
NEXGEL reportó ingresos récord en el Q3 2024 de 2,94 millones de dólares, marcando un incremento del 141% interanual y del 104% secuencial. El crecimiento fue impulsado por aumentos secuenciales de aproximadamente el 100% en productos de consumo de marca y en la fabricación por contrato. El margen de beneficio bruto mejoró al 43,6% desde el 28,2% en el Q3 2023. La compañía reportó una pérdida neta de 754.000 dólares y una pérdida de EBITDA ajustado de 347.000 dólares. El saldo de efectivo se situó en 1,10 millones de dólares, con 2 millones de dólares adicionales recaudados a través de una oferta directa registrada después del trimestre.
NEXGEL은 2024년 3분기 기록적인 수익 294만 달러를 보고하며, 전년 대비 141% 및 이전 분기 대비 104% 증가했음을 나타냈습니다. 성장은 브랜드 소비재와 계약 제조 모두에서 약 100%의 순차적 증가에 의해 주도되었습니다. 총 이익률은 2023년 3분기의 28.2%에서 43.6%로 개선되었습니다. 회사는 754,000달러의 순손실과 347,000달러의 조정된 EBITDA 손실을 보고했습니다. 현금 잔고는 110만 달러였으며 분기 후 등록된 직접 제공을 통해 추가로 200만 달러를 모금했습니다.
NEXGEL a annoncé un chiffre d'affaires record pour le T3 2024 de 2,94 millions de dollars, marquant une augmentation de 141 % par rapport à l'année précédente et de 104 % par rapport au trimestre précédent. La croissance a été stimulée par des augmentations séquentielles d'environ 100 % tant pour les produits de consommation de marque que pour la fabrication sous contrat. La marge brute a amélioré à 43,6 % contre 28,2 % au T3 2023. L'entreprise a signalé une perte nette de 754 000 dollars et une perte d'EBITDA ajusté de 347 000 dollars. Le solde de trésorerie s'élevait à 1,10 million de dollars, avec 2 millions de dollars supplémentaires levés par le biais d'une offre directe enregistrée après le trimestre.
NEXGEL berichtete von einem Rekordumsatz von 2,94 Millionen Dollar für das 3. Quartal 2024, was einem Anstieg von 141 % im Vergleich zum Vorjahr und 104 % im Vergleich zum Vorquartal entspricht. Das Wachstum wurde durch einen sequenziellen Anstieg von etwa 100 % bei sowohl Markenverbrauchsprodukten als auch der Vertragsherstellung getragen. Die Bruttomarge verbesserte sich auf 43,6 % im Vergleich zu 28,2 % im 3. Quartal 2023. Das Unternehmen berichtete von einem Nettoverlust von 754.000 Dollar und einem Verlust vor Zinsen, Steuern und Abschreibungen (EBITDA) von 347.000 Dollar. Der Kassenbestand betrug 1,10 Millionen Dollar, wobei nach dem Quartal zusätzlich 2 Millionen Dollar durch ein registriertes Direktangebot aufgenommen wurden.
- Record quarterly revenue of $2.94M, up 141% YoY and 104% QoQ
- Gross profit margin improved significantly to 43.6% from 28.2% YoY
- Adjusted EBITDA loss decreased to $347,000 from $464,000 YoY
- Successfully raised $2M through registered direct offering
- Both branded consumer products and contract manufacturing grew ~100% sequentially
- Net loss increased to $754,000 from $552,000 YoY
- Selling, general and administrative expenses increased 118% YoY to $2.1M
- Cost of revenues increased by 89.1% to $1.66M YoY
- Potential shareholder dilution from new share issuance of 727,272 shares
Insights
NEXGEL's Q3 2024 results demonstrate remarkable growth with
The company's recent
Quarterly revenue growth driven by a sequential increase of
Gross profit margin for the quarter was
LANGHORNE, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record third quarter revenue of
Third Quarter 2024 Financial Highlights:
- Net Revenue was
$2.94 million , compared to$1.22 million in Q3 2023 and$1.44 million in Q2 2024. - Gross Profit Margin was
43.6% , compared to28.2% in Q3 2023 and28.5% in Q2 2024. - Net loss was
$754,000 , compared to$552,000 in Q3 2023 and$979,000 in Q2 2024. - Adjusted EBITDA1 loss, a non-GAAP financial measure, was
$347,000 in Q3 2024, compared to$464,000 in Q3 2023 and$788,000 in Q2 2024. - Cash as of September 30, 2024, was
$1.10 million . Subsequent to the end of the quarter, the Company closed on a registered direct offering for gross proceeds of$2 million .
“The third quarter was yet another record quarter for the Company across all our key financial measures. Revenue increased
Third Quarter 2024 Financial Highlights
For the third quarter 2024, revenue totaled
Gross profit totaled
Gross profit margin for the third quarter of 2024 was
Cost of revenues increased by
Selling, general and administrative expenses increased by
Adjusted EBITDA1 loss, a non-GAAP financial measure, was approximately
Net loss for the third quarter 2024 was
As of September 30, 2024, the Company had a cash balance of approximately
As of November 13, 2024, NEXGEL had 6,790,777 shares of common stock outstanding, which number does not include the 727,272 shares of common stock we anticipate issuing in connection with our recent offering.
1. Adjusted EBITDA is a non-GAAP measure described in the section titled Non-GAAP Financial Measures” below and reconciled to the most directly comparable GAAP measure at the end of this release.
Third Quarter 2024 Financial Results Conference Call
Date: November 13, 2024
Time: 4:30 P.M. ET
Live Call: 1-800-225-9448 (U.S. Toll Free) or 1-203-518-9708 (International)
Webcast: Events and Presentations
For interested individuals unable to join the conference call, a replay will be available through August 28, 2024, by dialing + 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11157563. An archived version of the webcast will also be available for 90 days.
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Non-GAAP Financial Measures
Certain Non-GAAP financial measures are included in this press release. In the calculation of these measures, the Company excludes certain items, such as amortization of intangible assets, stock-based compensation, tax impact of adjustments, other unusual items and discrete items impacting income tax expense. The Company believes that excluding such items provides investors and management with a representation of the Company's core operating performance and with information useful in assessing its prospects for the future and underlying trends in the Company's operating expenditures and continuing operations. Management uses such Non-GAAP measures to evaluate financial results and manage operations. The release and the attachments to this release provide a reconciliation of each of the Non-GAAP measures referred to in this release to the most directly comparable GAAP measure. The Non-GAAP financial measures are not meant to be considered a substitute for the corresponding GAAP financial statements and investors should evaluate them carefully. These Non-GAAP financial measures may differ materially from the Non-GAAP financial measures used by other companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our expectation that our year-over-year and sequential revenue growth will continue in the fourth quarter and our quarterly Non-GAAP EBITDA* loss will narrow even further as we head into the holidays.. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2023, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@kcsa.com
NEXGEL, INC
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023
(Unaudited)
(in thousands, except share and per share data)
| September 30, 2024 | December 31, 2023 | |||||||
| ASSETS: | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 1,059 | $ | 2,700 | ||||
| Accounts receivable, net | 894 | 633 | ||||||
| Inventory | 1,778 | 1,319 | ||||||
| Prepaid expenses and other current assets | 879 | 400 | ||||||
| Total current assets | 4,610 | 5,052 | ||||||
| Goodwill | 1,124 | 1,128 | ||||||
| Intangibles, net | 839 | 326 | ||||||
| Property and equipment, net | 2,219 | 1,499 | ||||||
| Operating lease - right of use asset | 1,685 | 1,855 | ||||||
| Other assets | 95 | 95 | ||||||
| Total assets | $ | 10,572 | $ | 9,955 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 1,505 | $ | 1,233 | ||||
| Accrued expenses and other current liabilities | 609 | 398 | ||||||
| Deferred revenue | 179 | 20 | ||||||
| Current portion of note payable | 83 | 80 | ||||||
| Warrant liability | 109 | 146 | ||||||
| Contingent consideration liability | 271 | 439 | ||||||
| Financing lease liability, current portion | 58 | - | ||||||
| Operating lease liabilities, current portion | 234 | 233 | ||||||
| Total current liabilities | 3,048 | 2,549 | ||||||
| Operating lease liabilities, net of current portion | 1,589 | 1,727 | ||||||
| Financing lease liability, net of current portion | 323 | - | ||||||
| Notes payable, net of current portion | 626 | 513 | ||||||
| Total liabilities | 5,586 | 4,789 | ||||||
| Commitments and Contingencies (Note 16) | ||||||||
| Preferred stock, par value | - | - | ||||||
| Common stock, par value | 7 | 6 | ||||||
| Additional paid-in capital | 21,826 | 19,406 | ||||||
| Accumulated deficit | (17,146 | ) | (14,715 | ) | ||||
| Total NexGel stockholders’ equity | 4,687 | 4,697 | ||||||
| Non-controlling interest in joint venture | 299 | 469 | ||||||
| Total stockholders’ equity | 4,986 | 5,166 | ||||||
| Total liabilities and stockholders’ equity | $ | 10,572 | $ | 9,955 | ||||
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(Unaudited)
(in thousands, except share and per share data)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenues, net | $ | 2,940 | $ | 1,221 | $ | 5,647 | $ | 3,007 | ||||||||
| Cost of revenues | 1,658 | 877 | 3,678 | 2,546 | ||||||||||||
| Gross profit | 1,282 | 344 | 1,969 | 461 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | - | 6 | 78 | 90 | ||||||||||||
| Selling, general and administrative | 2,070 | 950 | 4,604 | 2,629 | ||||||||||||
| Total operating expenses | 2,070 | 956 | 4,682 | 2,719 | ||||||||||||
| Loss from operations | (788 | ) | (612 | ) | (2,713 | ) | (2,258 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest expense | (20 | ) | (3 | ) | (67 | ) | (13 | ) | ||||||||
| Interest income | - | 1 | 2 | 3 | ||||||||||||
| Other income | 39 | - | 40 | 3 | ||||||||||||
| Gain on investments | 5 | 44 | 62 | 168 | ||||||||||||
| Changes in fair value of warrant liability | 10 | 18 | 37 | 96 | ||||||||||||
| Total other income, net | 34 | 60 | 74 | 257 | ||||||||||||
| Loss before income taxes | (754 | ) | (552 | ) | (2,639 | ) | (2,001 | ) | ||||||||
| Income tax expense | - | - | - | - | ||||||||||||
| Net loss | $ | (754 | ) | $ | (552 | ) | $ | (2,639 | ) | $ | (2,001 | ) | ||||
| Less: Loss (income) attributable to non-controlling interest in joint venture | 61 | 2 | 208 | (58 | ) | |||||||||||
| Net loss attributable to NexGel stockholders | (693 | ) | (550 | ) | (2,431 | ) | (2,059 | ) | ||||||||
| Net loss per common share - basic | $ | (0.11 | ) | $ | (0.10 | ) | $ | (0.39 | ) | $ | (0.36 | ) | ||||
| Net loss per common share - diluted | $ | (0.11 | ) | $ | (0.10 | ) | $ | (0.39 | ) | $ | (0.36 | ) | ||||
| Weighted average shares used in computing net loss per common share - basic | 6,569,403 | 5,714,316 | 6,274,221 | 5,654,981 | ||||||||||||
| Weighted average shares used in computing net loss per common share – diluted | 6,569,403 | 5,714,316 | 6,274,221 | 5,654,981 | ||||||||||||
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(Unaudited)
(in thousands)
| Nine Months Ended September 30, | ||||||||
| 2024 | 2023 | |||||||
| Operating Activities | ||||||||
| Net loss | $ | (2,431 | ) | $ | (2,059 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Income (loss) attributable to non-controlling interest in joint venture | (208 | ) | 58 | |||||
| Depreciation and amortization | 328 | 103 | ||||||
| Changes in ROU asset and operating lease liability | 31 | 33 | ||||||
| Share-based compensation and restricted stock vesting | 271 | 120 | ||||||
| Gain on investment in marketable securities | (62 | ) | 168 | |||||
| Changes in fair value of warrant liability | (37 | ) | (96 | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (261 | ) | (936 | ) | ||||
| Inventory | (459 | ) | (588 | ) | ||||
| Prepaid expenses and other assets | (479 | ) | (227 | ) | ||||
| Accounts payable | 272 | 808 | ||||||
| Accrued expenses and other current liabilities | (132 | ) | (67 | ) | ||||
| Deferred revenue | 159 | 34 | ||||||
| Net Cash Used in Operating Activities | (3,008 | ) | (2,649 | ) | ||||
| Investing Activities | ||||||||
| Proceeds from sales of marketable securities | 62 | 5,340 | ||||||
| Capital expenditures | (374 | ) | (611 | ) | ||||
| Net cash paid for Asset acquisition | (400 | ) | - | |||||
| Net Cash (Used in) Provided by Investing Activities | (712 | ) | 4,729 | |||||
| Financing Activities | ||||||||
| Proceeds from margin line of credit | 345 | 89 | ||||||
| Proceeds from Rights offering | 1,950 | — | ||||||
| Investment by joint venture partner | 37 | |||||||
| Principal payment on financing lease liability | (36 | ) | — | |||||
| Change in contingent consideration liability | (164 | ) | — | |||||
| Principal payments of notes payable | (53 | ) | (4 | ) | ||||
| Net Cash Provided by Financing Activities | 2,079 | 85 | ||||||
| Net Decrease in Cash | (1,641 | ) | 2,165 | |||||
| Cash – Beginning of period | 2,700 | 1,101 | ||||||
| Cash – End of period | $ | 1,059 | $ | 3,266 | ||||
| Supplemental Disclosure of Cash Flows Information | ||||||||
| Cash paid during the year for: | ||||||||
| Interest | $ | 65 | $ | 7 | ||||
| Taxes | $ | — | $ | — | ||||
| Supplemental Non-cash Investing and Financing activities | ||||||||
| Shares issued in conjunction with asset acquisition | $ | 200 | $ | — | ||||
| Property and equipment financed under notes payable | $ | 165 | $ | — | ||||
| Property and equipment financed under financing leases | $ | 416 | $ | — | ||||
| Property and equipment contributed as capital investment to JV | $ | — | $ | 500 | ||||
| ROU asset and operating lease liabilities recognized upon consolidation of JV | $ | — | $ | 334 | ||||
RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES
(in thousands, except per share amounts)
CALCULATION OF EBITDA & ADJUSTED EBITDA
| Three Months Ended June 30, | Three Months Ended September 30, | ||||||||||||
| 2024 | 2024 | 2023 | |||||||||||
| Net (loss) income: | $ | (979 | ) | $ | (754 | ) | $ | (552 | ) | ||||
| Less: Loss (income) attributable to non-controlling interest in joint venture | 94 | 61 | 2 | ||||||||||
| Net loss attributable to NexGel stockholders | (885 | ) | (693 | ) | (550 | ) | |||||||
| Adjustments: | |||||||||||||
| Depreciation and amortization | 82 | 184 | 35 | ||||||||||
| Interest expense | 30 | 20 | 3 | ||||||||||
| Income tax expense | - | - | - | ||||||||||
| EBITDA | (773 | ) | (489 | ) | (512 | ) | |||||||
| Change in warrant liability(1) | (79 | ) | (11 | ) | (19 | ) | |||||||
| Share-based compensation expense(2) | 64 | 153 | 67 | ||||||||||
| Adjusted EBITDA: | $ | (788 | ) | $ | (347 | ) | $ | (464 | ) | ||||
| Nine Months Ended September 30, | ||||||||||
| 2024 | 2023 | |||||||||
| Net (loss) income: | $ | (2,639 | ) | $ | (2,001 | ) | ||||
| Less: Loss (income) attributable to non-controlling interest in joint venture | 208 | (58 | ) | |||||||
| Net loss attributable to NexGel stockholders | (2,431 | ) | (2,059 | ) | ||||||
| Adjustments: | ||||||||||
| Depreciation and amortization | 328 | 103 | ||||||||
| Interest expense, net | 65 | 10 | ||||||||
| Income tax expense | - | - | ||||||||
| EBITDA | (2,038 | ) | (1,946 | ) | ||||||
| Change in warrant liability (1) | (37 | ) | (96 | ) | ||||||
| Share-based compensation expense(2) | 271 | 120 | ||||||||
| Adjusted EBITDA: | $ | (1,804 | ) | $ | (1,922 | ) | ||||
| (1 | ) | This adjustment gives effect to non-cash warrant liability changes incurred during the periods. | |
| (2 | ) | The adjustments represent share-based compensation expense related to awards of stock options, restricted stock units, or common stock in exchange for services. Although we expect to continue to award stock in exchange for services, the amount of non-cash stock-based compensation is excluded as it is subject to change as a result of one-time or non-recurring projects. | |
FAQ
What was NEXGEL's (NXGL) revenue in Q3 2024?
What was NEXGEL's (NXGL) gross profit margin in Q3 2024?
How much capital did NEXGEL (NXGL) raise in their recent offering?
What was NEXGEL's (NXGL) net loss in Q3 2024?
